Researcher
Sébastien Anguille
- Research Expertise:Cancer; hematological malignancies; acute myeloid leukemia; immunotherapy; dendritic cells; gene-modified T cells including chimeric antigen receptor (CAR) T cell; translational research; clinical studies
- Keywords:T CYTOTOXIC LYMPHOCYTE, DENDRITIC CELLS, CLINICAL TRIAL, CANCER VACCINES, CANCER IMMUNOTHERAPY, ELECTROPORATION, Medicine
- Disciplines:Hematology, Cancer therapy
- Research techniques:Cell culture; multiparameter flow cytometry; ELISA and ELISpot; cytotoxicity experiments; mRNA electroporation; GMP production of dendritic cell vaccines and CAR-T cells
- Users of research expertise:Academia; biotech companies; pharmaceutical companies
Affiliations
- Laboratory for Experimental Hematology (LEH) (Research group)
Responsible
From1 Oct 2020 → Today - Laboratory for Experimental Hematology (LEH) (Research group)
Member
From1 Jan 2019 → 30 Sep 2020 - Vaccine & Infectious Disease Institute (VAXINFECTIO) (Research group)
Member
From1 Oct 2018 → 31 Dec 2018 - Vaccine & Infectious Disease Institute (VAXINFECTIO) (Research group)
Member
From1 Oct 2008 → 31 Jul 2013
Projects
1 - 10 of 16
- Development of a novel chimeric antigen receptor (CAR)-T cell therapy for acute myeloid leukemia.From1 Oct 2023 → TodayFunding: BOF - doctoral mandates
- BCMA immunoPET to predict and monitor treatment response to CAR-based cellular therapies in multiple myeloma.From1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Learning the design language of CAR structural components using a high-throughput screening method.From1 Sep 2022 → 28 Feb 2023Funding: Foreign Nonprofit organisations and equivalents
- Targeting the NF-κB pathway with targeted protein degradation for the treatment of hematological malignancies.From1 Sep 2022 → TodayFunding: Baekeland
- Flow Cytometry and Cell Sorting Core Facility Uantwerpen (FACSUA)From1 Jan 2022 → TodayFunding: BOF - research organisations
- MulTplex project: Innovating on combinatorial genetically engineered adoptive Tcell therapies against hematological diseases.From1 Nov 2021 → 31 Oct 2022Funding: Nonprofit institution or equivalents
- Preclinical development of novel chimeric antigen receptor (CAR)-modified cell-based immunotherapy approaches for hematological malignancies.From1 Oct 2021 → TodayFunding: BOF - doctoral mandates
- Post-transplant infusion of CD19 CAR-armored donor lymphocytes in adult patients with B-cell hematological malignancies: a phase I/IIa study.From1 Oct 2021 → TodayFunding: Nonprofit institution or equivalents
- ANCHOR project - Antigenspecific non signaling CARs as hemato-oncological remedy.From22 Jun 2021 → 22 Jun 2022Funding: Foundations, funds and other with scientific goal
- Identification and validation of T cell receptor (TCR) pairs for TCR-T cell therapy for AML and NHL (HEME TCR).From1 Jun 2021 → TodayFunding: VLAIO - research project companies
Publications
1 - 10 of 81
- Analysis of Wilms’ tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed(2023)
Authors: Sofie Gielis, Donovan Flumens, Maarten Versteven, Hans De Reu, Esther Bartholomeus, Jolien Schippers, Diana Campillo Davó, Zwi Berneman, Sébastien Anguille, Evelien Smits, et al.
Number of pages: 24 - In vitro expansion of Wilms’ tumor protein 1 epitope-specific primary T cells from healthy human peripheral blood mononuclear cells(2023)
Authors: Donovan Flumens, Maarten Versteven, Stefanie Peeters, Hans De Reu, Diana Campillo Davó, Yannick Willemen, Benson Ogunjimi, Vigor Van Tendeloo, Zwi Berneman, Sébastien Anguille, et al.
Pages: 1 - 18 - Disease perception is correlated with health-related quality of life in patients suffering from myelodysplastic syndromes(2023)
Authors: Bert Heyrman, Stef Meers, Ann De Becker, Achiel Van Hoof, Ann Van de Velde, Carlos Graux, Dominiek Mazure, Dominik Selleslag, Helena Maes, Jan Lemmens, et al.
Pages: 1 - 11 - Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in patients with cancer(2023)
Authors: Yana Debie, Jonas Van Audenaerde, Timon Vandamme, Lieselot Croes, Laure-Anne Teuwen, Greetje Vanhoutte, Elly Marcq, Lisa Verheggen, Debbie Le Blon, Maria Goossens, et al.
Pages: 635 - 646 - Cilta-cel or standard care in lenalidomide-refractory multiple myeloma(2023)
Authors: Jesus San-Miguel, Binod Dhakal, Kwee Yong, Andrew Spencer, Sébastien Anguille, Maria-Victoria Mateos, Carlos Fernandez de Larrea, Joaquin Martinez-Lopez, Philippe Moreau, Cyrille Touzeau, et al.
Pages: 335 - 347 - One-step CRISPR-Cas9-mediated knockout of native TCRαβ genes in human T cells using RNA electroporation(2023)
Authors: Donovan Flumens, Diana Campillo Davó, Ibo Janssens, Gils Roex, Jorrit De Waele, Sébastien Anguille, Eva Lion
Pages: 1 - 21 - Combined results of two cross-sectional surveys on the participation in clinical trials and the e-consent procedure in the landscape of haematology(2023)
Authors: Bert Heyrman, Stef Meers, Ann Van de Velde, Sébastien Anguille, Maurizio Arico, Giustino Varrassi
Pages: 1520 - 1531 - Anti-tumor potency of short-term interleukin-15 dendritic cells is potentiated by in situ silencing of programmed-death ligands(2022)
Authors: Maarten Versteven, Donovan Flumens, Diana Campillo Davó, Hans De Reu, Laura Van Bruggen, Vigor Van Tendeloo, Zwi Berneman, Harry Dolstra, Sébastien Anguille, Willemijn Hobo, et al.
- Two for one(2022)
Authors: Gils Roex, Diana Campillo Davó, Donovan Flumens, Philip Shaw, Hans De Reu, Eva Lion, Sébastien Anguille
Pages: 1 - 13 - Ciltacabtagene autoleucel for patients with triple-class exposed multiple myeloma(2022)
Authors: Michel Delforge, Marie-Christiane Vekemans, Julien Depaus, Nathalie Meuleman, Ann Van de Velde, Isabelle Vande Broek, Sophie Vandervennet, Sandra Van Hoorenbeeck, Evelien Moorkens, Danielle Strens, et al.
Pages: 1 - 4